INBX earnings analysis
What we found in INBX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, working capital, and free cash flow cannot be quantified from the provided filing text. Operationally, the company continues to advance 2 therapeutic candidates, and its ozekibart BLA is under FDA review. The principal updated risks are regulatory review uncertainty, Form 483 inspection observations, and the history of a grade 5 hepatotoxicity event that previously triggered a partial clinical hold.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Pipeline remains focused on 2 candidates
- The company reported that 2 therapeutic candidates, ozekibart (INBRX-109) and INBRX-106, are currently in active clinical trials, while its BLA for ozekibart is under FDA review.
- Controls operating effectively
- Management stated that disclosure controls and procedures were operating effectively at the reasonable assurance level as of June 30, 2026.
- No material control changes
- The filing states that there were 0 material changes to internal control over financial reporting during the quarter ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No products and approval uncertainty
- The company has 0 products on the market and depends on regulatory approval and successful commercialization of its therapeutic candidates to achieve profitability. Its ozekibart BLA remains under FDA review, with no assurance of approval on the expected timeline or at all.
- FDA inspection observations
- FDA clinical inspections related to the ozekibart BLA generated Form 483 observations for the company and some ChonDRAgon investigators. Although corrective and preventive actions have been implemented, the observations could delay review or result in a complete response letter.
- Clinical safety and trial-delay risk
- The ChonDRAgon trial experienced a grade 5 hepatotoxicity event in early 2023 that triggered protocol stopping rules and a partial clinical hold; the FDA lifted the hold in April 2023 after protocol amendments.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing does not provide explicit forward guidance.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Inhibrx reported a Q1 2026 net loss of $33.4 million, an improvement of 23% compared to a net loss of $43.3 million in Q1 2025. Operating expenses decreased significantly by 28% due to reduced research and development…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INBX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever